Quratis

Quratis Gross Margin

The Gross Margin of Quratis (348080.KQ) as of Nov 5, 2026 is -206.46 %. In the previous year, Gross Margin was -2,095.50 % — a change of -90.15% (higher).

Gross Margin

-206.46 %

YoY

-90.15%

Last updated:

Gross Margin of Quratis is 2025 -206.46 % . Gross Margin of Quratis was 2024 -2,095.50 % . It decreases by -90.15% higher compared to the previous year.

Quratis's gross margin stands at -206.5%, down from 12.0% several years earlier.

The Quratis Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2020
100.00 KRW
Jan 1, 2021
12.02 KRW
Jan 1, 2022
63.10 KRW
Jan 1, 2023
-151.94 KRW
Jan 1, 2024
-2,095.50 KRW
Jan 1, 2025
-206.46 KRW
The Quratis Gross Margin history
YEARGross MarginYoY
-206.46 %-90.15%
-2,095.50 %+1,279.21%
-151.94 %-340.78%
63.10 %+425.07%
12.02 %-87.98%
100.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quratis Stock analysis

What does Quratis do? Quratis, Inc. generates revenue through the manufacture and sale of vaccines, including tuberculosis vaccines for adults and adolescents and COVID-19 vaccines, as well as peptide nucleic acid complex products. The company provides Cell Penetrating Peptide (CPP) platform services to clients in the pharmaceutical sector. Revenue streams are derived from the development and research activities related to vaccine products, with a focus on tuberculosis and COVID-19 vaccine research for adult and adolescent populations. Quratis targets pharmaceutical companies and research institutions seeking advanced vaccine development solutions. The company's CPP platform services are utilized by clients requiring innovative delivery systems for therapeutic applications. Revenue is generated through direct sales of vaccine products and service contracts for CPP platform usage, primarily serving the pharmaceutical industry segment focused on vaccine development and research. The firm's primary products include tuberculosis vaccines for adults and adolescents, COVID-19 vaccines, and peptide nucleic acid complex. These products are sold to pharmaceutical companies and research organizations. The company's revenue model combines product sales with service-based offerings, where the Cell Penetrating Peptide (CPP) platform services represent a key revenue stream alongside vaccine sales. Quratis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Quratis stock

Gross Margin of Quratis is -206.46 % in 2025.

Gross Margin of Quratis changed from -2,095.50 % to -206.46 %, representing a -90.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Quratis since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Quratis with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Quratis

All Key Metrics — Quratis